Review

New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma

Lilia Dimitrov1,2*, Christopher S. Hong2*, Chunzhang Yang2, Zhengping Zhuang2*, John D. Heiss2*

1. Barts and the London School of Medicine and Dentistry, Greater London, E1 2AD, United Kingdom
2. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA

* Equal contribution

Corresponding authors: Zhengping Zhuang, M.D., Ph.D. P: (301) 435-8445; F: (301) 402-0536; E: zhuangp@ninds.nih.gov. John D. Heiss, M.D. P: (301) 594-8112; F: (301) 402-0380; E: heissj@ninds.nih.gov

© 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.

Received: 2014.11.12; Accepted: 2014.12.30; Published: 2015.01.20

Abstract

In the last five years, IDH1 mutations in human malignancies have significantly shaped the diagnosis and management of cancer patients. Ongoing intense research efforts continue to alter our understanding of the role of the IDH1 mutation in tumor formation. Currently, evidence suggests the IDH1 mutation to be an early event in tumorigenesis with multiple downstream oncogenic consequences including maintenance of a hypermethylator phenotype, alterations in HIF signalling, and disruption of collagen maturation contributing to a cancer-promoting extracellular matrix. The most recent reports elucidating these mechanisms is described in this review with an emphasis on the pathogenesis of the IDH1 mutation in glioma. Conflicting findings from various studies are discussed, in order to highlight areas warranting further research. Finally, the latest progress in developing novel therapies against the IDH1 mutation is presented, including recent findings from ongoing phase I clinical trials and the exciting prospect of vaccine immunotherapy targeting the IDH1 mutant protein.

Key words: IDH1 protein, glioma, DNA methylation, HIF1A protein, molecular targeted therapy, review

Introduction

Glioma is a broad term that includes primary malignant brain tumors of many types. Great effort has been expended to determine the genetic basis of these tumors, with the expectation that this knowledge will pave the way for the development of highly targeted therapies that will improve their generally poor prognosis.

Glioma has three main histological subtypes. Astrocytoma is the most common, accounting for 70% of all cases, while oligodendroglioma comprises 9%, and ependymoma 6% [1]. Tumors derived from mixed cell types make up most of the remaining cases. Glioblastoma (GBM) is the most malignant and most common type of astrocytoma, representing 55% of all cases of glioma. GBM treatment has traditionally involved surgery and radiation, with chemotherapy being of little additional value [2]. A recent randomized clinical trial demonstrated that the inclusion of temozolomide to surgery and radiotherapy resulted in a median survival of 15 months, 2.5 months more than surgery and radiation alone, and this regimen has become the current standard for GBM [3]. Life expectancy remains short, spurring additional research and development of more effective therapeutic strategies for GBM.

In 2008, The Cancer Genome Atlas (TCGA) conducted a genome-wide profile study, which identified, for the first time, mutations in the gene of isocitrate dehydrogenase 1 (IDH1) in GBM tumor samples [4]. The novel discovery in GBM of a mutation in a gene expressing an enzyme involved in cellular metabolism mirrored findings in non-central nervous
system (CNS) tumors of mutation of genes expressing the metabolic enzymes succinate dehydrogenase and fumarate hydratase [5]. Since then, IDH1 mutations have been linked to other histopathological forms of glioma and to non-CNS malignancies.

This review describes the current role of IDH1 mutations in human malignancies, including glioma. IDH1 mutation-specific relationships with oncogenic signalling pathways are detailed to identify pathogenic events underlying tumor formation. Additionally, this update includes recent and ongoing therapies targeting the IDH1 mutant protein.

**A clinical overview of IDH1 in human malignancy**

**Glioma**

GBMs are divided into primary and secondary types. Both are histologically identical, so clinical features are used to distinguish them. Primary GBM is by far the more common, accounting for 80% of cases. It presents as a GBM and predominates in older adults. Secondary GBMs evolve from lower-grade tumors (grade II diffuse astrocytoma or grade III anaplastic astrocytoma) and are typically seen in younger patients [6].

In the landmark TCGA study, the authors sequenced 20,661 protein-coding genes in 22 primary and secondary GBM tumor samples and used high-density oligonucleotide arrays to look for amplifications and deletions. They found that five of the samples (22%) had a heterozygous missense mutation in the IDH1 gene, a single base substitution of guanine for adenine, leading to arginine substituting for histidine at codon site 132 (R132H) in the mutant IDH1 protein. Strikingly, this mutation was present in 5 of the 6 secondary GBMs but none of the 16 primary GBMs. A follow-up targeted sequence analysis of an additional 127 tumors found the same IDH1 mutation in 13 of the samples with 4/5 (80%) of the secondary GBM tumors demonstrating the IDH1 mutation. Overall, the IDH1 mutation was found in 12% of the 149 tumors that were analysed. In a recent literature review, the IDH1 mutation was found in 5.6% of primary GBMs analysed across all studies (75/1345 tumors), and in 76% (94/123 tumors) of secondary GBMs, supporting the original findings of the TCGA study [7]. The IDH1 mutation is also prevalent in lower grade gliomas, occurring in over 70% of grade II tumors [8], and 62-80% of grade II-III oligodendro-gliomas, grade II-III oligoastrocytomas, and grade III astrocytomas [7].

The TCGA study also importantly found that IDH1 mutations were more frequent in younger patients. The median age of patients with tumors harboring IDH1 mutations was 33.2 years, starkly contrasting the median age of 55.3 years in patients with wild type tumors. This study also demonstrated that in GBM patients, the IDH1 mutation conferred a survival advantage compared to IDH1 wild type GBM, with a median overall survival of 3.8 years in the former and 1.1 years in the latter. This finding has been replicated in other studies, with a survival of 2.6 years in IDH1 mutated tumors compared to just 1.2 years in wild type IDH1 tumors [9]. It is unclear whether IDH1 status alone is responsible for this survival advantage or whether other characteristics of secondary GBM improve its prognosis over primary GBM. Recently, Beiko et al (2014) demonstrated that IDH1 mutations were associated with higher rates of total surgical resection of enhancing regions in grade III and IV astrocytomas [10]. Furthermore, maximal resection of total tumor volume, including non-enhancing areas, led to improved overall survival in IDH1 mutated tumors but not in wild type counterparts. These results suggest that greater amenability to complete surgical resection may contribute to the improved prognosis of patients with IDH1 mutated gliomas. Complete surgical resection of total tumor volume (enhancing and non-enhancing areas) may be of greater significance to patient prognosis in IDH1 mutated tumors, compared to wild types. Further investigations are required to elucidate additional mechanisms behind the improved survival seen in patients with IDH1 mutated gliomas. This may be aided by a study comparing the survival of patients with secondary gliomas having the IDH1 mutation with the survival of patients with secondary IDH1 wild type gliomas.

IDH1 represents a gene that shows differential expression between primary and secondary GBMs. PTEN loss, EGFR amplification, and loss of heterozygosity (LOH) of chromosome 10 are associated with primary GBM while ATRX mutations, loss of p53, and LOH of chromosome 19 are common in secondary GBM [6, 11-14]. However, the IDH1 mutation predicts secondary GBM better than these other mutations predict their respective GBM subtypes.

Extensive genomic profiling has identified that around 90% of IDH1 mutations involve the R132H substitution [15, 16]. There may be some selection pressure for R132H, as this mutation is associated with the lowest levels of the compound 2-hydroxyglutarate (2-HG), which is lethal at high doses [17]. Of the remaining 10% of IDH1 mutations, 4.3-4.7% are due to arginine being replaced with cysteine (R132C), 1.9-2.1% with glycine (R132G), 1.6-1.7% with serine (R132S), 0.6-0.8% with leucine (R132L), and 0.3% with glutamine (R132Q) [16, 18]. Although no studies have compared patient outcomes among
different IDH1 R132 mutations, R132S- and R132L-transfected human embryonic kidney cells produce significantly higher levels of 2-HG and exhibit markedly reduced cell viabilities compared to R132H-transfected cells, in vitro [16]. In addition, the specific type of IDH1 mutation appears to correspond to distinct histological types suggesting functional differences between mutations. For example, R132C mutations occur more frequently in astrocytoma than in oligodendroglioma [19]. The type of other genetic mutations co-occurring with the IDH1 mutation also influences the histological type of glioma. For example, astrocytomas tend to feature IDH1 and TP53 mutations, while IDH1 mutated oligodendrogliomas frequently have co-deletions of chromosomes 1p and 19q [20].

Different patterns of the IDH1 mutation between primary and secondary GBM, as well as between other grades of astrocytomas, and between other types of gliomas, is very useful diagnostically, helping to differentiate between histological subtypes which can often be subject to human error [21]. As well as providing patients with more accurate diagnosis and prognosis, more precise characterization of molecular features could open the door to a whole host of new individualised treatments.

Non-CNS malignancies

IDH1 mutations are also present in some tumors originating in cells outside of the CNS. In a sample of 224 patients with acute myeloid leukaemia (AML), 9% of tumors possessed the IDH1 mutation [22]. IDH mutations are more prevalent in AML if IDH2 mutations are also considered, with rates between 15-33% [23-25]. IDH1/2 mutations have also been found in 5% of patients with myelodysplastic syndrome (MDS), 8.8% with myeloproliferative neoplasms (MPN) and just under 10% of patients with secondary AML [26]. Unlike in GBM, IDH1 mutations have a negative impact on prognosis in MPN and MDS [27].

In a study, over one-half of central chondrosarcomas, central chondromas, and periosteal chondromas displayed IDH1/2 mutations [28]. This link between IDH mutations and connective tissue tumors was reported by the same group that identified IDH mutations to occur in patients with Ollier disease and Maffucci syndrome. These mainly pediatric disorders are characterized by the development of multiple tumor types and by somatic mosaicism of the IDH1 mutation. The majority of Ollier disease and Maffucci syndrome patients exhibit the R132C IDH1 mutation, in contrast to most secondary GBMs, which harbour the R132H mutation [29]. Interestingly, both Ollier disease and Maffucci syndrome are associated with the development of benign cartilaginous tumors, AML, and gliomas [30]. In addition, 10% of cholangiocarcinomas harbor IDH1 or 2 mutations; the prognostic significance of the mutation in this malignancy is unknown [31]. Although less well documented, other CNS tumors including ganglioglioma and primitive neuroectodermal tumor have also been linked with the IDH1 mutation [32, 33].

Physiological function of IDH1

In humans, IDH occurs as 3 isozymes: Idh1, Idh2 and Idh3 [34]. These isozymes are encoded by five genes: IDH1, IDH2, IDH3A, IDH3B and IDH3G. All are metabolic enzymes expressed by eukaryotic cells that act on the substrate isocitrate, converting it to alpha-ketoglutarate (a-KG) via oxidative decarboxylation. The reactions catalysed by IDH1 and IDH2 are reversible and use NADP+ as an electron acceptor leading to the production of NADPH [35]. IDH1 acts in the cell cytoplasm and peroxisomes whereas IDH2 and IDH3 are found in the mitochondrial matrix. The formation of non-mitochondrial NADPH by IDH1 is thought to be an important mechanism for limiting cellular oxidative damage. NADPH also acts as a reducing agent in lipid biosynthesis [36, 37]. The product of the IDH1 forward reaction, a-KG, is an intermediate in the tricarboxylic acid cycle (TCA) and is also involved in nitrogen transportation, oxidation reactions, and amino acid formation. In conditions of hypoxia, the reverse reaction is favored, in which IDH1 catalyzes the conversion of a-KG to isocitrate which can in turn be converted to acetyl-CoA for lipid metabolism [38, 39]. Additionally, IDH1 regulates glucose-stimulated insulin secretion [40].

Pathogenesis of IDH1 in malignancy

Introduction

Mutations to IDH1 appear to occur early on in glioma development, preceding loss of chromosomes 1p and 19q [40]. From a total of 321 biopsies taken over time from patients with grade II and III gliomas, there were no instances where TP53 mutations or 1p/19q co-deletions were found to develop prior to IDH1 mutation. This may be due to a strand asymmetrical mechanism, in which the IDH1 mutation is found on the template strand while TP53 mutations are on the coding strand and are thus only able to be transcribed after DNA replication [41].

Although the current understanding of IDH1 mutations in tumorigenesis remains incomplete, several important advances have been made that elucidate key molecular mechanisms. Unlike other metabolic enzymes associated with cancer such as fumarate hydratase and succinate dehydrogenase, the IDH1 mutation is a gain-of-function mutation, con-
ferring neo-morphic activity upon IDH1 [4]. In a pivotal study profiling IDH1 wild type and mutant (R132H) glioma cells with liquid chromatography-mass spectrometry, Dang et al (2009) demonstrated that the mutant glioma cells express high levels of the metabolite 2-hydroxyglutarate (2-HG) [42]. Cellular levels of 2-HG in the wild type cells were usually below 0.1 mM, whereas levels in IDH1 mutated glioma cells reached 35 mM. The authors demonstrated that mutant IDH1 protein catalyzes the reduction of α-KG to the R-enantiomer of the metabolite, 2-HG (R-2-HG). Specifically, the mutation reduces the affinity of the IDH1 active site for isocitrate while concomitantly increasing it for NADPH and α-KG [43]. Reduced affinity for isocitrate occurs as a result of alterations to a binding site residue that forms hydrogen bonds between the alpha and beta carboxyl groups of isocitrate [43]. Consequently, the reverse reaction of IDH1 (α-KG to isocitrate) is favored but rather than carboxylate, the mutant enzyme reduces α-KG to form 2-HG (Fig. 1).

2-HG exists as two possible enantiomers, both of which occur physiologically as metabolic by-products [44]. In physiological conditions, the R-type is formed when gamma-hydroxybutyrate is converted to succinic semialdehyde while the S-type is formed during the conversion of oxaloacetate to L-malate in the TCA cycle [45, 46]. To date, only the R-enantiomer has been associated with IDH1 mutant proteins. Interestingly, R-2-HG formation catalyzed by mutant IDH1 requires heterozygosity of the IDH1 locus as homozygous IDH1 mutations show significantly reduced levels of R-2-HG [42, 47]. It has been suggested that mutant IDH1 may source α-KG produced by the wild type enzyme, contributing to high levels to R-2-HG [47]. This has been recapitulated by Brooks et al (2014) who demonstrated that the heterodimer of wild type and mutant IDH1 proteins had a $K_m$ approximately 11-fold lower than that of the mutant homodimer [48]. Several studies have shown that high levels of R-2-HG are able to mediate the changes seen in IDH1 mutants and as such, R-2-HG has been termed an “onco-metabolite” [49]. In an experiment using TF-1 leukemia cells, introduction of cell-permeable R-2-HG inhibited differentiation in response to erythropoietin (EPO) and induced growth factor resistance [27]. Both of these outcomes are important hallmarks in the formation of leukemia. This study demonstrated that continuously elevated levels of R-2-HG were needed to maintain tumor phenotype in IDH1 mutant cells as withdrawal of R-2-HG restored the normal differentiation response to EPO and growth factors. Further support for the role of 2-HG comes from the observation that patients with L-2-hydroxyglutaric aciduria, an inborn error of metabolism characterized by elevated levels of S-2-HG, have a higher risk of developing gliomas [50]. Interestingly however, patients with D-2-hydroxyglutaric aciduria, a similar metabolic disorder that is characterized by elevated R-2-HG, are not at increased risk for glioma or formation of other tumors [51]. The reason for this discrepancy is unclear and is an area requiring further investigation.

![Figure 1. Of the three IDH isozymes, only IDH1 exists in the cytosol while IDH2 and IDH3 function within the mitochondria. Under normal conditions, cytosolic isocitrate is converted into α-KG by the wild type IDH1 enzyme with concurrent reduction of NADP+. Subsequently, α-KG can re-enter Kreb’s cycle within the mitochondria or remain in the cytosol as an essential substrate for PHD. Among its many functions, in conditions of normoxia, PHD utilizes oxygen as a co-substrate and hydroxylates proline residues on HIF1-α, initiating proteasomal degradation via the VHL ubiquitin-ligase protein complex. Unlike its wild type counterpart, the mutant IDH1 protein exhibits neo-morphic activity and catalyzes conversion of α-KG into R-2-HG an “onco-metabolite” that promotes tumorigenesis through multiple pathways.](http://www.medsci.org)
A number of potential mechanisms have been proposed to explain how R-2-HG produced by the mutant IDH1 protein promotes tumor formation. Epigenetic modification, via inhibition of α-KG-dependent dioxygenases leading to DNA and histone hypermethylation, has been at the forefront of research efforts [52]. Additional mechanisms implicated in tumor formation in IDH1 include inhibition of several groups of prolyl hydroxylases (PHD), leading to HIF1-a activation and alterations in collagen formation. Evidence for these findings is subsequently discussed in greater detail.

**Targeting of hypoxia-inducible factors**

Hypoxia-inducible factors (HIFs) are transcription factors that activate an array of genes important in the cellular response to hypoxia. Targeted downstream effects include angiogenesis, glucose metabolism and cell proliferation. HIF1 is a heterodimer made up of the HIF1-a and HIF1-b subunits, the former of which is active during hypoxic conditions but is unstable and degraded by von-Hippel Lindau protein (VHL) in the presence of oxygen. When oxygen levels are sufficient, the 2-KG-dependent PHD, Eg1N, hydroxylates proline residues on HIF1-a, creating a binding site for the VHL ubiquitin-ligase protein complex, which subsequently ubiquitinates HIF1-a for proteasomal degradation. In conditions of hypoxia, the HIF1-a PHD is inhibited as it requires oxygen as a co-substrate for enzymatic activity [53]. As such, HIF1-a degradation is circumvented and instead HIF1-a combines with the corresponding beta subunit, translocates to the nucleus, and activates target genes that facilitate cell survival in hypoxia and also may contribute to tumor formation (Fig. 2).

Considering that the Eg1N PHD is 2-KG-dependent, it was initially proposed that IDH1 mutations could cause tumor formation due to failure of HIF degradation secondary to impaired HIF1-a proline residue hydroxylation (Fig. 2) [54]. Increased levels of the transcription factor HIF1-a and its target genes have been found in the brain cells of IDH1 R132H knock-in mice [55]. More recently, it was shown that transfection of the IDH1 mutation into glioma cell lines upregulated HIF1-a and increased cell proliferation [56]. The authors suggested that this was mediated by transcriptional activity of HIF1-a dependent nuclear factor-κB (NF-κB) as mutant IDH1-mediated activation of NF-κB was abolished in a HIF1-a-dependent manner.

It is well established that HIF activation has an important role in tumor formation. However recent work suggests that the picture is more complex than this, with evidence that HIF1-a and HIF2-a have an antagonistic relationship [57]. In renal cell carcinoma, HIF1-a and HIF2-a have been shown to have tumor suppressive and promoting effects, respectively [58]. These observations have extended to IDH1 mutated glioma. In contrast to aforementioned studies demonstrating elevated levels of HIF1-a in IDH1 mutated glioma, other groups have found HIF1-a levels to be low. R-2-HG has been shown in astrocytes to act as a partial agonist for Eg1N, resulting in lower HIF levels but interestingly increased astrocyte proliferation [59]. The possibility that the IDH1 mutation drives cell proliferation via diminished HIF expression has been corroborated in several glioma studies. Williams et al (2011) looked at 120 human glioma samples and found that HIF1-a was only upregulated in a small subset of IDH1 mutated gliomas and was generally limited to necrotic areas [60]. Immunohistochemical analysis showed that in non-necrotic areas that were strongly reactive for the R132H IDH1 mutation, there was no evidence of HIF1-a overexpression. HIF upregulation in necrotic areas may explain the elevated levels of HIF1-a in the mouse model described by Sasaki et al, (2012) [55]. Mouse models of the IDH1 mutation have been associated with hemorrhage and high perinatal mortality and therefore it is difficult to exclude that the observed upregulation of HIF and corresponding target genes were not secondary to these events.

**Figure 2.** High levels of R-2-HG produced by the mutant IDH1 protein inhibit hydroxylation of HIF1-a by PHD. As such, HIF1-a persists, combines with the beta subunit, and translocates to the nucleus, where it induces transcription of hypoxia-related genes that may also promote oncogenic transformation and cell survival.

Undoubtedly, further work is needed to clarify the role of HIFs in IDH1 mutated glioma. Although traditionally considered as oncogenic, there is mounting evidence that HIFs have tumor suppressive
properties in both CNS and hematologic malignancies [61]. As such, pharmacological inhibition of Eg1N activity has been proposed as a potential target for IDH1 mutant glioma and may be an important topic of future study [59].

**Aberrant collagen maturation and stability**

In addition to HIF regulation, PHDs are also involved in the post-translational modification of collagen, a process essential for collagen maturation and stability [62]. Three main a-KG-dependent PHD families are implicated in this activity: the leprecan prolyl-3-hydroxylases, the prolyl-4-hydroxylase alpha subunits, and the procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) lysyl-5-hydroxylases. PHDs hydroxylate proline residues on type IV collagen, which is required for formation of the collagen triple helix whereas the lysyl-hydroxylates hydroxylate lysine residues that permit cross-linking between fibrils. Type IV collagen contributes to the integrity of blood brain barrier (BBB) and is specifically found in the basement membrane between astrocytes and endothelial cells. In the animal model of the IDH1 R132H mutation described earlier, mice were found to have higher levels of immature type IV collagen [55]. As a-KG-dependent post-translational changes to collagen occur in the endoplasmic reticulum (ER), it has been proposed that inhibition of a-KG by R-2-HG may cause accumulation of misfolded collagen in the ER, triggering an ER stress response that may contribute to the early lethality seen in IDH1 mutant embryos (Fig. 3). Additionally, impairment of perivascular type IV collagen may promote progression and breakdown of the physiological BBB in IDH1 mutated gliomas [55, 63, 64]. Given mutations in collagen synthesizing genes have been associated with IDH mutations in non-CNS tumors [65], future research may uncover similar findings in glioma as well as better define the role of IDH1 mutations in BBB disruption.

**A hypermethylator phenotype**

DNA methylation, in particular CpG island hypermethylation, is a well-established hallmark of certain human cancers [66]. Methylation at these sites results in gene silencing, raising the possibility that tumor suppressor genes can be targets of this silencing and thus promote tumor formation. Recently, a quantitative analysis of the methylation status of five known tumor suppressor genes was performed in glioma cells and in glioma cell-free DNA from serum, which found that tumor methylation of PARP-1, SHP-1, DAPK-1 and TIMP-3 genes was positively correlated with tumor grade and negatively correlated with prognosis [67].

A subset of the 272 GBM tumors from TCGA and additional low-grade gliomas (LGG) analyzed for DNA methylation were found by Noushmehr et al (2010) to have overlapping methylated DNA loci, suggestive of a pattern of CpG island methylation [68]. The authors termed this the glioma-CpG island methylator phenotype (G-CIMP). They found that the G-CIMP phenotype was strongly associated with the IDH1 mutation and was more common in younger patients and associated with improved prognosis. Similar associations between global hypermethylation and IDH1/2 mutations have been observed in IDH1/2 mutated AML cells [69]. The G-CIMP phenotype has also recently been found to include tumor suppressive miRNAs with the finding that methylation of miR-148a is associated with IDH1 mutated glioma cells [70].

**Figure 3.** The hydroxylation of proline residues on pre-collagen fibrils by PHD is required for proper triple helix formation and maturation of type IV collagen. Disruption of PHD by R-2-HG produced by mutant IDH1 leads to accumulation of misfolded collagen, triggering a pro-apoptotic endoplasmic reticulum (ER) stress response. Additionally, as type IV collagen is found in the perivascular spaces of the brain, abnormal collagen build-up may contribute to breakdown of the blood brain barrier (BBB) in IDH1 mutated glioma.
There is evidence to suggest that the association between hypermethylation and IDH1 mutations may be causal. Transfection of mutant IDH1 into immortalized primary human astrocytes resulted in the hypermethylator phenotype [71]. Similarly, introduction of ectopic mutant IDH1 into normal human astrocytes caused total genome hypermethylation as seen in IDH1 mutated LGG [72]. In the IDH1 mutation mouse model described by Sasaki et al (2012), mice with the mutant gene in the myeloid lineage alone had a similar hypermethylation pattern as seen in AML patients with IDH1/2 mutations and interestingly developed hematological malignancy-associated features of anemia, splenomegaly and extramedullary hematopoiesis [73]. More recently, Kernytsky and colleagues (2014) demonstrated that in vitro treatment with a small molecule inhibitor (AGI-6780) reversed histone and genomic DNA methylation patterns seen in an erythroleukemia model of IDH2 (R140Q) mutated TF-1 cells [74]. Importantly, the authors showed that exposure to AGI-6780 led to therapeutic demethylation of gene signatures that are known to be hypermethylated in hematologic malignancies. As such, further studies are required to corroborate whether genes hypermethylated by IDH1 and IDH2 mutations are indeed tumor suppressor genes. From a clinical standpoint, in order for G-CIMP to be useful prognostically, precise promoter loci must be defined.

**IDH1 mutation-mediated silencing of TET2**

The leading mechanism attributed to the observed hypermethylation phenotype in IDH1 mutants involves silencing of the α-KG-dependent DNA modifying enzyme, Tet methylcytosine dioxygenase 2 (TET2). This myeloid tumor suppressor enzyme is one of three enzymes (TET1, TET2, TET3) dependent on α-KG to hydroxylate 5-methylcytosine (5mc) to 5-hydroxymethylcytosine (5hmC) during DNA demethylation [75]. It has been proposed that because R-2-HG is very similar structurally to α-KG, it may act as a direct competitive inhibitor of α-KG-dependent dioxygenases such as TET2 [59, 76, 77]. TET2 inhibition may encourage DNA hypermethylation through impaired DNA demethylation, leading to the hypermethylation phenotype (Fig. 4). TET2 has been a particular focus of research because it has been linked to hematological malignancies. Heterozygous loss-of-function TET2 mutations are seen in 10-25% of myeloid disorders such as AML, MDS, and chronic myelomonocytic leukemia (CMML) [78].

Genetic and epigenetic profiling of AML patients has revealed that TET2 mutated AML cells possess a hypermethylation signature that may contribute to impaired differentiation and elevation of stem cell markers [69]. However hypermethylation in response to loss of TET2 function has not been consistently found across studies. In fact several studies have reported the reverse pattern, with hypomethylation in TET2 mutated AML cells and hypermethylation in TET2 wild type cells [79, 80]. In another study, no difference in methylation was observed between wild type and mutant TET2 CMML cells [81]. As such, it is evident that although loss of TET2 is strongly linked to malignancy, the precise mechanism underlying this observation is undoubtedly still unclear [47]. Other factors likely contribute to whether loss of TET2 leads to a hypermethylator phenotype and tumor formation.

![Figure 4](http://www.medsci.org)

**Figure 4.** Under normal conditions, TET2 utilizes α-KG as a substrate to hydroxylate 5-methylcytosine (5mc) to 5-hydroxymethylcytosine (5hmC) during DNA demethylation. α-KG also binds to the JmjC domain of histone demethylases, which function to demethylate lysine residues on histone tails and subsequently regulate gene transcriptional activity. R-2-HG produced by the mutant IDH1 protein acts as a competitive inhibitor of TET2 and JmjC, promoting a hypermethylator phenotype that maintains an undifferentiated tumor state.

Experimental findings have been mixed in terms of the effect of IDH1 mutations on TET2 activity. Evidence of reduced levels of 5hmC in IDH1 mutated cells compared to wild types has been reproduced across several studies in glioma cells [71, 77] and in AML cells [69]. Transfection of TET2-expressing AML cells with the IDH1 mutation nearly halved 5hmC levels. Similarly, expression of the IDH1 and IDH2 mutations in cell lines derived from GBM led to reduced 5hmC levels whereas expression of IDH1 and TET1/2 wild types increased 5hmC levels, suggesting
an inverse relationship between the IDH1 mutation and 5hmC levels. In the IDH1 mutant mouse model, mice expressing the IDH1 mutation in brain cells alone were found to have lower levels of 5hmC [55].

Perhaps, the most significant study demonstrating that the tumorigenic effects of the IDH1 mutation arise due to TET2 dysfunction was the discovery that IDH1/2 and TET2 mutations were mutually exclusive in 300 AML samples [69]. Furthermore, similar mutation signatures were found in IDH1 and TET2 mutants, involving over 60% of the genetic loci, suggesting overlapping effects between the two mutations. However, these results have not been replicated in glioma where one group demonstrated that none of 35 IDH1 wild type LGGs was found to have TET2 mutations [82]. Interestingly, however, the IDH1 wild types were associated with TET2 promoter methylation, which was not the case for any of the 38 IDH1 mutated LGGs. This finding suggested that IDH1 mutations and TET2 methylation could be mutually exclusive, with TET2 methylation providing an alternative mechanism for tumorigenesis in IDH1 wild type LGG. Exclusivity of IDH1 and TET2 mutations in leukemia has been suggested to result from a clonal disadvantage of IDH1 mutations for TET2 mutants [27]. Future studies may elucidate whether the same holds true in glioma.

On the other hand, numerous groups have reported findings against inhibition of TET2 by R-2-HG. Muller et al (2012) found that 61% of gliomas (wild type and IDH1 mutants) showed non-existent levels of 5hmC whereas high levels of 5hmC were found in 33% of IDH1 mutants [83]. Low 5hmC levels were associated with nuclear exclusion of TET1, perhaps by the promoter methylation mechanism observed by Kim et al (2011) [82]. Interestingly, nuclear exclusion occurred more frequently in IDH1 wild types whereas IDH1 mutant gliomas were associated with nuclear accumulation of TET1. Although this counteracts a R-2-HG-mediated inhibition of TET, this study focused on TET1, which has been far less studied in human malignancy compared to TET2. Secondly, TET2 knockout and IDH1 gain-of-function mouse models have been shown to differ to a wide extent phenotypically, suggesting these mutations may contribute to tumor formation in a parallel rather than in a cooperative manner.

Histone hypermethylation and the Jumonji transcription factor family

The four histone proteins H2A, H2B, H3 and H4 have an important scaffolding role for DNA, packaging it into structural units called nucleosomes [84]. Histone tails are the sites at which numerous modification reactions occur, with histone tail methylation being a major focus of current cancer research. Histone methylation is important for modifying chromosome structure and can either activate or inhibit transcription of associated genes. For example, methylation of the histone residues H3K4, H3K36 and H3K79 activate euchromatin for transcription whereas the reverse is true for residues H3K9, H3K27, and H4K20 [85, 86]. Histone methylation is tightly controlled by a balance between histone methyltransferases and histone demethylases with the latter removing methyl groups from lysine residues on histone tails that are mono-, bi-, and tri-methylated. Alterations of this fine balance have significant effects on gene expression [87].

There is evidence that certain histone demethylases may act as tumor suppressors, with inhibition of specific histone demethylases implicated in clear cell renal carcinoma, MDS and AML [88, 89]. R-2-HG appears to have an inhibitory effect on a number of histone demethylases including members of the Jumonji transcription factor family (JMJD2A, JMJD2C and JHDM1A/FBXL11), which may contribute to tumorigenesis (Fig. 4) [76]. Furthermore, evidence of hypermethylation of the H3 family of histones H3K4, H3K9, H3K27, H3K36 and H3K79 has been found following mutant IDH1 expression or R-2-HG exposure in multiple human cancer cell lines as well as in normal astrocytes and adipocyte precursors [71, 90, 91]. Lu et al (2012) demonstrated hypermethylation of histone H3K9 in 3T3 fibroblast cells that were exposed to R-2-HG, and this was accompanied by reduced differentiation into mature adipocytes [90]. In the same study they showed immortalized astrocytes transfected with the IDH1 mutation had increased levels of histone methylation. Notably, the particular sites of histone methylation overlapped with those found in IDH1 mutant glioma cells.

Conversely, histone demethylases may also promote cancer formation. Overexpression of JHDM2A has been associated with poor prognosis in colorectal cancer [92], while overexpression of JMJD2C has been demonstrated in esophageal cancer [93], MALT-lymphoma [94] and breast cancer [95]. Furthermore, the oncogenic and oncosuppressive effects of particular histone demethylases depend upon the cell type in which these enzymes are expressed or inhibited [87]. Interestingly, IDH1 wild type gliomas also show evidence of histone hypermethylation. As previously discussed, H3K9 hypermethylation occurs in IDH1 mutated gliomas, but it has also been found in their wild type counterparts [90]. Trimethylation of H3K9 has been strongly linked to IDH1 mutations in oligodendrogliaomas and grade II astrocytomas, but has not been associated with IDH1 mutations in grade III/IV astrocytomas, despite the majority of these...
tumors exhibiting evidence of the hypermethylation phenotype [96]. It may be the case that histone hypermethylation is a common feature broadly across all gliomas rather than being a mechanism by which IDH1 exerts its tumorigenic effects. Alternatively, histone hypermethylation may be propagated by IDH1 mutations in some glioma subtypes (e.g. oligodendrogliomas) but via different mechanisms in others (grade III/IV astrocytomas).

**Therapies targeting the IDH1 mutant protein**

**Small molecule inhibitors targeting the IDH1 mutant protein**

Small molecule inhibitors represent a viable strategy for targeting oncogenic enzymes, demonstrated initially by the development of imatinib, a compound inhibiting the bcr-abl fusion protein in hematopoietic malignancies [97]. The first small molecule inhibitor of the mutated IDH1 protein was reported by Popovici-Muller et al (2012) who performed a high-throughput screening of compounds against the R132H IDH1 mutant protein homodimer [98]. Further refining potential candidates with a-KG and NADPH assays, the authors identified a molecule, compound 35, which demonstrated potent inhibition of R-2-HG production in R132H U87 GBM cells and R132C HT1080 chondrosarcoma cells. IC50 values against the two mutant isoforms were less than 0.5 μM in both cell lines while the IC50 for the wild type IDH1 protein was over 20 μM. Additionally, intraperitoneal administration of compound 35 into U87 tumor xenograft mouse models yielded improved IC50 values of 0.07 μM against tumor R-2-HG production. To date, no further studies of compound 35 have been reported by the original authors or other groups. However, given mounting evidence that the mutant IDH1 protein acts as a heterodimer with the wild type protein, this study’s approach to screen against a mutant protein homodimer was not ideal.

Recently, a quantitative high throughput compound screen identified ML309 as a potent inhibitor of the R132H mutant IDH1 enzyme [99]. The drug acts a competitive inhibitor of the mutant IDH1, competing with a-KG for the enzymatic active site. As such, drug treatment in GBM cell lines yielded significantly lower levels of R-2-HG in a dose-dependent manner. Additionally, ML309 demonstrated preferential activity against the mutant IDH1 over the wild type, with an IC50 of 96 nM for the former and 35 μM for the latter, respectively. More recently, ML309 was shown to inhibit the R132C IDH1 mutation with similar efficacy [100]. Furthermore, ML309 exhibited good aqueous solubility, was stable in human plasma, and had a moderate half-life of 3.76 hours. Notably, ML309 administration in healthy mice showed absence of BBB penetration. No studies have examined the efficacy of ML309 in a GBM xenograft model where BBB disruption by the tumor would theoretically permit accumulation of the drug in areas of dense tumor.

Similarly, via high throughput screening, another compound, AGI-5198, has been identified as a potent inhibitor of R132H mutated IDH1 [101]. AGI-5198 exhibited higher selectivity than ML309 against mutant IDH1 with an IC50 of 70 nM and an IC50 of >100 μM for the wild type enzyme and may be administered orally. AGI-5198 administration was able to reduce R-2-HG levels in a dose-dependent manner in R132H-mutated TS603 grade III glioma cells and effectively prevented colony formation. Importantly, the drug did not do the same for wild type IDH1 expressing glioma cell lines, further supporting the selectivity of AGI-5198. In addition, in support of an association of IDH1 mutations with the hypermethylation phenotype, ex vivo treatment of TS603 glioma cells with AGI-5198 induced differentiation of nestin-positive neural progenitor cells into glial fibrillary acidic protein (GFAP) and aquaporin-4 (AQ-4)-positive astrocytes with a concomitant reduction in histone methylation associated with these latter genes. Oral administration of AGI-5198 in mice with xenografted subcutaneous tumors also significantly reduced intratumoral R-2-HG levels, diminished immunohistochemical staining of histone methylation, and increased expression of astroglial differentiation genes. Further development of AGI-5198 has led to development of AG-120 and AG-221 (Agios Pharmaceuticals, Cambridge, MA), orally administered drugs targeting IDH1 and IDH2 mutations, respectively. As such, a multicentre, open-label, dose escalation phase 1 clinical trial was started in March 2014, studying the safety and tolerability of AG-120, in patients with advanced hematologic malignancies and advanced solid tumors. Likewise, a phase 1 trial for AG-221 was launched in September 2013 for advanced hematologic cancers. Preliminary results from the AG-221 phase 1 trial have demonstrated good patient tolerance with no dose-limiting toxicities. Reportedly, 14/25 patients responded objectively to treatment and 6 patients experienced complete remissions (Press release by Agios Pharmaceuticals, dated April 6, 2014; accessed at http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=1916041). In addition, AG-221 treatment has correlated with reductions in plasma R-2-HG levels. Similar early results are highly anticipated for the AG-120 trial.

Another group recently identified a small mol-

---

**http://www.medsci.org**
precursor for a-KG and subsequently, R-2-HG. A d-
converts glutamine to glutamate, the latter being the
non-competitive inhibition of glutaminase, which
strategy for inhibiting mutant IDH1 enzymatic activ-
gesting that targeting glutaminase may be a potential
inhibition of glutaminase inhibits glioma cells, sug-
ent manner. Furthermore, these results were also re-
duced 2-HG levels exceeded that against PDE5
anti-2-HG activity may have resulted from off-target
effects. It is yet to be seen whether the doses of
zaprinst required for therapeutic efficacy lead to in
vivo toxicity. Additionally, it is unknown whether
zaprinst has any ability to penetrate the BBB. How-
ever, a handful of studies have demonstrated that
inhibition of glutaminase inhibits glioma cells, sug-
gest that targeting glutaminase may be a potential
strategy for inhibiting mutant IDH1 enzymatic activ-
ity [103-105].

Vaccine immunotherapy against the IDH1
mutant protein

Development of glioma-specific vaccine thera-
ies has garnered interest as a way of therapeutically
modulating the native immune system to recognize
and destroy tumor cells. To date, none of the phase 1
or 2 clinical trials of vaccine immunotherapies have
specifically sought to target the IDH1 mutated
epitope. Furthermore, in their phase I/IIa trial of an
autologous formalin-fixed tumor vaccine for newly
diagnosed GBM (administered with fractionated ra-
diotherapy and temozolomide), Ishikawa and co-
leagues did not find any significant association be-
tween vaccine response (induction of delayed-type
hypersensitivity) and IDH1 R132H mutation status
[106].

Recently, however, a group published their pre-
clinical work in development of a vaccine im-
munotherapy targeting the IDH1 mutant protein
[107]. Using 15-mer peptides from the R132H IDH1
mutant protein loaded onto MHC class II complexes,
vaccination of MHC-humanized transgenic mice
produced robust Th1-cell responses as evidenced by
increased interferon-gamma production and detecta-
ble levels of anti-IDH1 (R132H) in the serum. Notably,
these effects were not seen with homologous peptides
from the IDH1 wild type protein. Furthermore, these
findings were reproduced in IDH1 (R132H) mutated
sarcomas in mouse xenografts, resulting in potent
tumor growth suppression and absence of overt tox-
icities. Interestingly, the authors screened 25 patients
with R132H IDH1 mutated gliomas and found de-
tectable levels of IFN-gamma producing Th1 cells
against this specific epitope in four patients. Howev-
er, it is unclear whether the presence of an anti-IDH1
mutant T-cell response in these select patients con-
ferred any survival benefit. HLA typing of all 25 pa-
tients was non-specific suggesting the mutant IDH1
protein is not limited to any particular HLA class II
type. Taken together, although only a single study,
there will likely be increased efforts to develop novel
immunotherapies that target the IDH1 mutant pro-
tein. It is yet to be seen whether the results of this
study are reproducible in tumors protected by the
BBB. Furthermore, many questions remain regarding
the prognostic significance of patients who are able to
mount an IDH1 mutant specific immune response
without intervention.

Conclusions

Just six years since the IDH1 mutation was first
discovered in GBM, our understanding of the preva-
ence and pathogenesis of this mutation in both CNS
and non-CNS tumors has grown at a rapid rate. It is
well established that IDH1 is an important mutation
in LGG and secondary GBM, and this knowledge is
being readily applied to patient care. Classifications
based upon IDH1 mutation status are increasingly
being used in clinical practice [7]. Diagnosis of IDH1
mutations has been able to provide important diag-
nostic and prognostic information for patients, re-
moving some of the burden of uncertainty. Furthermore, as previously mentioned, two Phase-1 multicentre dose escalation trials are underway that are evaluating an oral medication targeting the IDH1 mutant protein in patients with hematological and solid malignancies. As more precise molecular targets become elucidated, the hope is that this will provide a much-needed boost for treatment options.

As demonstrated in this review, multiple potential mechanisms for the role of IDH1 in tumorigenesis have been proposed. The majority of research has focused on the role of R-2-HG-mediated effects on a number of key cellular processes. This has revealed that R-2-HG has a diverse set of targets that in theory, could explain how IDH1 mutations mediate tumor formation. The data described in this review have thus far revealed, unsurprisingly, that a single simple explanation is unlikely. Both DNA and histone methylation generate epigenetic changes resulting in altered cellular developmental programs that may be unique to IDH1 mutated tumors. It is also likely that HIFs play some role, although current evidence suggests that this may be counter-intuitive to what we understand of HIF functioning in other cancers. Much of the research has focused on the a-KG-dependent dioxygenase TET2, but it should be noted that there are over 70 a-KG-dependent dioxygenases that could be potentially involved in the oncogenesis of IDH1 mutated malignancies. To truly understand the effects of the IDH1 mutation, additional research is needed to cover the whole spectrum of targets, rather than reliance on previously investigated mechanisms. Although many additional questions remain, research in the oncogenic mechanisms of the IDH1 mutation has provided rich new findings for the field of cancer biology. With continued research efforts, it is likely these questions may soon be answered.

Acknowledgements
This work was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH).

Abbreviations
GBM: Glioblastoma; TCGA: The Cancer Genome Atlas; IDH1: Isocitrate dehydrogenase; CNS: Central nervous system; LOH: Loss of heterozygosity; 2-HG: 2-hydroxyglutarate; AML: Acute myeloid leukemia; MDS: Myelodysplastic syndrome; MPN: Myeloproliferative neoplasms; a-KG: Alpha-ketoglutarate; TCA: Tricarboxylic acid cycle; R-2-HG: R-2-hydroxyglutarate; EPO: Erythropoietin; PHD: Prolyl hydroxylases; HIFs: Hypoxia-inducible factors; VHL: von-Hippel Lindau; NF-kB: nuclear factor-kB; PLOD: Procollagen-l-lysine, 2-oxoglutarate 5-dioxygenase; BBB: Blood brain barrier; ER: Endoplasmic reticulum; G-LCIMP: Glioma-CpG island methylator phenotype; TET: Tet methylcytosine dioxygenase; 5mc: 5-methylcytosine; 5hm: 5-hydroxymethylcytosine; CMML: Chronic myelomonocytic leukemia; GFAP: Glial fibrillary acidic protein; AQ-4: Aquaporin-4; PDE5: Phosphodiesterase-5.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Dolecek TA, Propp JM, Stroup NE, Kruchock C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol. 2012; 14 Suppl 5: v1-49. doi:10.1093/neuonc/nos218.
2. Walker MD, Alexander E, Jr., Hunt WE, MacCarty CS, Mahaley MS, Jr., Mealey J, Jr., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of neurosurgery. 1978; 49: 333-43. doi:10.3171/jns.1978.49.3.0333.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352: 987-96. doi:10.1056/NEJMoa043330.
4. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-8. doi:10.1038/nature07385.
5. Frezza C, Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Seminars in cancer biology. 2009; 19: 4-11. doi:10.1016/j.semcancer.2008.11.008.
6. Ogihara K, Kleihues P. Genetic pathways to primary and secondary glioblastoma. The American journal of pathology. 2007; 170: 1445-53. doi:10.2353/ajpath.2007.070011.
7. Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical focus. 2013; 34: E2. doi:10.3171/2012.12.FOCUS12355.
8. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta neuropathologica. 2008; 116: 597-602. doi:10.1007/s00401-008-0455-2.
9. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH1 mutations predict longer lifetime and response to temozolomide in secondary glioblastoma. Cancer science. 2012; 103: 269-73. doi:10.1111/j.1349-7006.2012.02134.x.
10. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology. 2014; 16: 81-91. doi:10.1093/neuonc/not159.
11. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. IDH1 mutant glioblastoma: a clinicopathological, molecular, and radiological study. Acta neuropathologica communications. 2014; 2: 19.
12. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Laboratory investigation; a journal of technical methods and pathology. 2000; 80: 65-72.
13. Nakamura M, Yang P, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. Journal of neuropathology and experimental neurology. 2000; 59: 539-43.
14. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta neuropathologica. 2012; 124: 615-25. doi:10.1007/s00401-012-1031-3.
15. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendrogial differentiation and age: a study of 1010 diffuse gliomas. Acta neuropathologica. 2009; 118: 469-74. doi:10.1007/s00401-009-0561-9.
16. Pusch S, Schweizer L, Beck AC, Lehrliner JM, Weisheit S, Balss J, et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta neuropathologica communications. 2014; 2: 19. doi:10.1186/2051-5960-2-19.
17. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular
35. Geisbrecht BV, Liang X, Morrell JC, Schulz H, Gould SJ. The mouse gene
38. Koh HJ, Lee SM, Son BG, Lee SH, Ryoo ZY, Chang KT, et al. Cytosolic
33. Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S, Clifford SC.
29. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, et al.
27. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al.
23. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al.

Int. J. Med. Sci. [59x107]Journal of biological chemistry. 1999; 274: 25814-20.

PDCR encodes a peroxisomal delta(2), delta(4)- dienoyl-CoA reductase. The
Reductive glutamine metabolism by IDH1 mediates lipogenesis under
NADP+-dependent isocitrate dehydrogenase plays a key role in lipid
Wanders RJ. Peroxisomal beta- oxidation of polyunsaturated fatty acids in
doi:10.1007/s11010-007-9421-x.

677-87. doi:10.1093/emboj/17.3.677.

reduction of double bonds at even positions. The EMBO journal. 1998; 17:
dehydrogenase. Molecular and cellular biochemistry. 2007; 302: 27- 34.

Oncogene. 2013; 32: 3091-100. doi:10.1038/onc.2012.315.

isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic
myeloid leukemia with NPM1 mutation without FLT3 internal tandem
duplication. Science. 2013; 339: 1621-5. doi:10.1126/science.1231677.

Mutations of IDH1 and IDH2 genes in early and accelerated phases of
M, et al. Opposing effects of HIF1alpha and HIF2alpha on chromaffin cell

212
for initiation of its assay during early development. Development. 2004; 131: 1619-28. doi:10.1242/dev.003037.

64. Rautavaauma K, Takalouso K, Sormunen R, Myllyharju J, Kirvikko KL, Samuelevich R. Peri-ovarian aggregation of type IV collagen and early lethality in lysyl hydroxylase 3 null mice. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 14120-5. doi:10.1073/pnas.0404966101.

65. Targary PS, Bui-S, Cooke S, Van Loo P, Wedge DC, Pillay N, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature genetics. 2013; 45: 923-6. doi:10.1038/ng.2668.

66. Suzuki H, Yamamoto E, Maruyama T, Niinuma T, Kai M. Biological significance of CpG island methylation phenotype. Biochemical and biophysical research communications. 2014. doi:10.1016/j.bbrc.2014.07.007.

67. Zhang L, Wang M, Wang W, Mo J. Incidence and prognostic value of multiple gene promoter methylations in gliomas. Journal of neuro-oncology. 2014; 116: 23-31. doi:10.1007/s11060-013-1201-5.

68. Nourmehr H, Weisenberger DJ, Diefes K, Phillips HS, Fujikawa J, Kerman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010; 17: 510-22. doi:10.1016/j.ccr.2010.04.004.

69. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylating phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010; 18: 588-600. doi:10.1016/j.ccr.2010.05.016.

70. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, et al. Tumor suppressor miR-148a is silenced by CpG island hypermethylation in IDH1 mutant gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. doi:10.1158/1078-0432.CCR-14-0234.

71. Tawara S, Rotke G, Gornik A, Wahlefeld F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483: 479-83. doi:10.1038/nature10866.

72. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of immortal brain tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer research. 2001; 61: 4956-60.

73. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle O, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010; 17: 510-22. doi:10.1016/j.ccr.2010.04.004.

74. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, et al. IDH2 mutations in oligodendrogliomas and high grade astrocytomas. Journal of neuropathology and experimental neurobiology. 2013; 72: 298-306. doi:10.1177/0022387812489913.

75. Li G, Bollig-Fischer A, Kreile B, van de Vijver MJ, Abrams J, Ellersieck MP, et al. Genetic amplification and oncogene expression of the GAS1 histone demethylase gene in breast cancer. Oncogene. 2009; 28: 4941-50. doi:10.1038/ons.2009.297.

76. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, et al. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high grade astrocytomas. Journal of neuropathology and experimental neurobiology. 2013; 72: 298-306. doi:10.1177/0022387812489913.

77. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

78. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

79. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

80. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

81. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

82. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

83. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

84. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

85. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

86. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

87. Davis M, Pragani R, Popovic-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.